Compare Ascendis Pharma A/S (ASND) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Charles Schwab Corporation Common Stock — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Charles Schwab Corporation Common Stock trades at $103.71 (market cap $179.34B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 10.1× Ascendis Pharma A/S's market cap, and Charles Schwab Corporation Common Stock pays a 1.24% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SCHW | |
|---|---|---|
Market Cap | $17.74B | $179.34B |
Sector | Health | Financials |
52-Week High | $277.18 | $107.21 |
52-Week Low | $163.32 | $85.35 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Charles Schwab (SCHW) trades at $103.12, up 1.19% today, near its pivot point of $102 with bullish technical momentum. The stock shows strong fundamentals with a 37.99% net income margin and 21.79% ROE, supported by three consecutive quarterly earnings beats. Recent news highlights a Zacks upgrade to Strong Buy and a four-year high in the Schwab Trading Activity Index, reflecting robust retail engagement.
Outlook remains positive with a consensus price target of $122.71 implying 19% upside, though overbought RSI signals near-term caution. Risks include interest rate sensitivity and competitive pressures, but institutional bullishness and expanding prediction market initiatives offer growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
